NASDAQ:TYME - Tyme Technologies Stock Price, Forecast & News

Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."

Tyme Technologies Inc (NASDAQ:TYME) announced its quarterly earnings data on Monday, November, 4th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.02. View Tyme Technologies' Earnings History.

Tyme Technologies is scheduled to release their next quarterly earnings announcement on Monday, February 10th 2020. View Earnings Estimates for Tyme Technologies.

1 brokerages have issued 12-month price objectives for Tyme Technologies' shares. Their forecasts range from $10.00 to $10.00. On average, they anticipate Tyme Technologies' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 420.8% from the stock's current price. View Analyst Price Targets for Tyme Technologies.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tyme Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tyme Technologies.

Media stories about TYME stock have been trending positive recently, InfoTrie reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Tyme Technologies earned a daily sentiment score of 3.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Tyme Technologies.

Tyme Technologies saw a drop in short interest in December. As of December 31st, there was short interest totalling 6,730,000 shares, a drop of 5.2% from the December 15th total of 7,100,000 shares. Based on an average trading volume of 448,600 shares, the short-interest ratio is presently 15.0 days. Approximately 13.1% of the shares of the company are sold short. View Tyme Technologies' Current Options Chain.

Some companies that are related to Tyme Technologies include Homology Medicines (FIXX), Stoke Therapeutics (STOK), Frequency Therapeutics (FREQ), CannTrust (CNTTF), Provention Bio (PRVB), Applied Therapeutics (APLT), ANI Pharmaceuticals (ANIP), Cytokinetics (CYTK), Urogen Pharma (URGN), ImmunoGen (IMGN), Basilea Pharmaceutica (BPMUF), Omeros (OMER), DiaMedica Therapeutics (DMCAF), Flexion Therapeutics (FLXN) and Processa Pharmaceuticals (PCSA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Tyme Technologies investors own include Bausch Health Companies (BHC), Karyopharm Therapeutics (KPTI), OpGen (OPGN), Rigel Pharmaceuticals (RIGL), Aurora Cannabis (ACB), New Age Beverages (NBEV), Novavax (NVAX), Ovid Therapeutics (OVID), Viking Therapeutics (VKTX) and Canopy Growth (CGC).

Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TYME stock can currently be purchased for approximately $1.92.

Tyme Technologies has a market capitalization of $214.95 million. The company earns $-32,980,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Tyme Technologies employs 11 workers across the globe.View Additional Information About Tyme Technologies.

The official website for Tyme Technologies is http://www.tymeinc.com/.

Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-461-2315 or via email at [email protected]